Fig. 4

SJP induces ALKBH5 expression in H/R cardiomyocytes, resulting in aberrant m6A modification (n = 3). a SJP inhibited m6A modification in H/R-treated H9c2 cells. b ALKBH5 mRNA amounts in H/R-treated H9c2 cells by PCR. c and d ALKBH5 protein amounts in H/R-treated H9c2 cells assessed by immunoblot. Data are mean ± SEM. ^*P < 0.05 versus Blank group; ^#P < 0.05 versus H/R group; ^&P < 0.05 versus SJP group; ^{^}P < 0.05 versus TMP group. e m6A modification levels in the ALKBH5 overexpression assay. ^*P < 0.05 versus NC + H/R group; ^#P < 0.05 versus ALKBH5-overexpression + H/R group. f m6A modification levels after transfection with ALKBH5 shRNA. ^*P < 0.05 versus shRNA-Ctrl + H/R group; ^#P < 0.05 versus shRNA-ALKBH5 + H/R group